Multivariate analyses showing the association of MOLST form completion with ICU admission, chemotherapy, any hospice admission, and hospice admission for >3 days
| . | ICU admission . | Chemotherapy . | Hospice . | Hospice for >3 d . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . |
| MOLST form completion (early vs late/never) | 0.21 | 0.11-0.39 | <.0001 | 0.24 | 0.10-0.59 | .002 | 2.69 | 1.66-4.43 | <.0001 | 2.50 | 1.49-4.17 | <.001 |
| Age (continuous, per year) | 0.95 | 0.93-0.97 | <.0001 | 0.98 | 0.96-1.00 | .10 | 1.03 | 1.02-1.05 | .0006 | 1.04 | 1.01-1.06 | .001 |
| Race (Nonwhite vs White) | 1.07 | 0.50-2.29 | .85 | 0.52 | 0.19-1.40 | .20 | 0.80 | 0.39-1.61 | .53 | 1.16 | 0.54-2.49 | .71 |
| Number of comorbidities (continuous) | 1.18 | 1.04-1.35 | .01 | 0.92 | 0.78-1.09 | .35 | 1.00 | 0.89-1.12 | .97 | 1.07 | 0.94-1.21 | .33 |
| Diagnosis (MDS vs AML) | 1.45 | 0.82-2.58 | .20 | 0.38 | 0.17-0.88 | .02 | 0.81 | 0.49-1.36 | .43 | 0.71 | 0.40-1.27 | .25 |
| Geographical location (rural vs urban) | 1.03 | 0.57-1.87 | .92 | 0.74 | 0.35-1.55 | .42 | 0.76 | 0.45-1.31 | .33 | 0.83 | 0.45-1.54 | .56 |
| New diagnosis (vs relapsed/refractory) | 0.66 | 0.26-1.66 | .38 | 1.04 | 0.32-3.39 | .95 | 1.39 | 0.59-3.28 | .45 | 1.00 | 0.38-2.59 | .99 |
| . | ICU admission . | Chemotherapy . | Hospice . | Hospice for >3 d . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . | AOR . | 95% CI . | P . |
| MOLST form completion (early vs late/never) | 0.21 | 0.11-0.39 | <.0001 | 0.24 | 0.10-0.59 | .002 | 2.69 | 1.66-4.43 | <.0001 | 2.50 | 1.49-4.17 | <.001 |
| Age (continuous, per year) | 0.95 | 0.93-0.97 | <.0001 | 0.98 | 0.96-1.00 | .10 | 1.03 | 1.02-1.05 | .0006 | 1.04 | 1.01-1.06 | .001 |
| Race (Nonwhite vs White) | 1.07 | 0.50-2.29 | .85 | 0.52 | 0.19-1.40 | .20 | 0.80 | 0.39-1.61 | .53 | 1.16 | 0.54-2.49 | .71 |
| Number of comorbidities (continuous) | 1.18 | 1.04-1.35 | .01 | 0.92 | 0.78-1.09 | .35 | 1.00 | 0.89-1.12 | .97 | 1.07 | 0.94-1.21 | .33 |
| Diagnosis (MDS vs AML) | 1.45 | 0.82-2.58 | .20 | 0.38 | 0.17-0.88 | .02 | 0.81 | 0.49-1.36 | .43 | 0.71 | 0.40-1.27 | .25 |
| Geographical location (rural vs urban) | 1.03 | 0.57-1.87 | .92 | 0.74 | 0.35-1.55 | .42 | 0.76 | 0.45-1.31 | .33 | 0.83 | 0.45-1.54 | .56 |
| New diagnosis (vs relapsed/refractory) | 0.66 | 0.26-1.66 | .38 | 1.04 | 0.32-3.39 | .95 | 1.39 | 0.59-3.28 | .45 | 1.00 | 0.38-2.59 | .99 |
AML, acute myeloid leukemia; ED, emergency department; ICU, intensive care unit; MDS, myelodysplastic syndrome; MOLST, Medical Orders for Life-Sustaining Treatment; OR, Odds Ratio; CI, Confidence Interval.